Related Experiment Video

Updated: Jul 19, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma

T Wölfel1, M Hauer, J Schneider

  • 1Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, Mainz, Germany.

Science (New York, N.Y.)
|September 1, 1995
PubMed

Insights

A mutated cyclin-dependent kinase 4 (CDK4) protein was found to be a tumor-specific antigen in melanoma, triggering an immune response. This mutation disrupts cell-cycle regulation and offers a potential target for cancer therapies.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Melanoma is a significant form of skin cancer.
  • Tumor-specific antigens can be recognized by the immune system.
  • Cyclin-dependent kinase 4 (CDK4) plays a role in cell-cycle regulation.

Purpose of the Study:

  • To identify tumor-specific antigens in human melanoma.
  • To investigate the role of mutated CDK4 in melanoma.
  • To explore the immunogenicity of mutated CDK4.

Main Methods:

  • Identification of tumor-specific antigens using autologous cytolytic T lymphocytes (CTLs).
  • Analysis of mutated CDK4 allele presence in melanoma tissues and patient lymphocytes.
  • Characterization of the mutation's effect on CDK4 inhibitor binding.

Main Results:

  • A mutated CDK4 was identified as a tumor-specific antigen recognized by HLA-A2.1-restricted CTLs.
  • The mutated CDK4 allele was found in melanoma cells and metastasis, but not in patient lymphocytes.
  • The R24C mutation in CDK4 disrupted p16INK4a binding but not p21 or p27KIP1 binding.
  • The same mutation was detected in one additional melanoma case.

Conclusions:

  • Mutation of CDK4 can generate a tumor-specific antigen.
  • CDK4 mutations can disrupt cell-cycle regulation mediated by p16INK4a.
  • Mutated CDK4 represents a potential target for melanoma immunotherapy.

More Related Videos

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...